Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3085)	5/27/1999 7:27:00 PM
From: Art Vandelay AIA	Respond to of 10280

One area many are neglecting is those drugs that couldn't make it all the way to FDA approval. To the extent that SEPR can eliminate side effects or work on dosages, there is another application for SEPR's ICE technology. Amazingly, they are still lightyears ahead of big pharma and competitors in this area, though logic would dictate that JNJ, SGP, and LLY, at a minimumm, would have learned by now. But let's try to keep it quiet for awhile, please, as SEPR is busy building more value. I'm more than happy to wait for notoriety while I accumulate more cash.